PPARG and pulmonary arterial hypertension: Additionally, addition of the PPARγ agonist rosiglitazone prevents hyperoxia-induced alveolar simplification [16–18], pulmonary inflammation [17], airway hyperreactivity [16], and pulmonary hypertension [18].